Skip to main content

Advertisement

Table 5 Summary of the detection of ADA and NAb in the enrolled patients

From: CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Case number The time of collection (Blood sample, weeks) ADA NAb
29 30 + +
69 30 +
102 6 + +
120 12 +
139 0 +a +
139 12 +
193 6 + +
234 6 + +
242 12 +
438 0 +a
467 0 +a +
510 0 +a +
  1. ADA, anti-drug antibodies; NAb, neutralizing antibodies
  2. aPre-existing ADA: ADA present in samples from treatment-naïve subjects or ADA in pre-dose (CMAB009) subject samples